home > ict > spring 2020 > a digital approach to enrolment
International Clinical Trials

A Digital Approach to Enrolment

ICT: What is the current market need for greater patient recruitment strategies?

Barbara and Nathalie: Recruitment of patients and healthy volunteers for clinical trials is a well-known bottleneck. The success and timelines for attracting and enrolling patients have a direct impact on the time it takes to get a drug or medical device to the market. Delays result in higher operating costs, losses in sales, and many other drawbacks. In recent years, there has been increasing demand for specialised patient recruitment services in Europe. Approaches that apply for US-based clinical trials cannot be copied Ďas isí for clinical trials in Europe.

In Europe, it is challenging to navigate through the complex regulatory landscape. There are few or no rules and only minimal guidelines with respect to patient recruitment strategies. Additionally, substantial cultural differences across countries require country-specific recruitment approaches and a high degree of customisation.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:

There are no comments in regards to this article.

 You must be a member of the site to make a comment.
About the authors

Barbara Díhaene brings to the company over 10 years of experience in innovation management. In 2015, she was one of the founders of the patient management company Akcelis, which was acquired by Pivotal early 2020. Together with Nathalie Niclaus, she developed innovative patient-centric solutions.

As Co-Founder of Akcelis, Nathalie Niclaus designed and implemented practical solutions to overcome some of the hurdles in clinical trials. She combined all her experience and knowledge of clinical trials to develop innovative solutions and strategies for successful clinical trial patient recruitment and retention.
Print this page
Send to a friend
Privacy statement
News and Press Releases

ICON Releases Environmental, Social and Governance Report

ICON announced today the release of its 2020 Environmental, Social and Governance (ESG) Report.
More info >>

White Papers

Mouse Models for Evaluation of Vaccines and Therapeutics Against Staphylococcal Infections

IBT Bioservices

Introduction Staphylococcus aureus (SA) is a ubiquitous, formidable Gram-positive pathogen associated with skin and soft tissue, as well as lifethreatening systemic infections. SA is a leading cause of hospital- and community-associated infections worldwide, affecting humans and animals. The wide range of pathologies reflects the diverse abilities of this microbe to escape the innate and adaptive immune response using virulence factors. Since its first emergence in the 1960s methicillin-resistant SA (MRSA) has become endemic in hospitals and healthcare settings worldwide. In the 1990s, community associated MRSA strains (CA-MRSA) emerged, and are spreading worldwide posing a major global challenge.
More info >>




©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement